JP2015183004A - パーキンソン病を治療するための吸入式医薬組成物及びその調製法 - Google Patents
パーキンソン病を治療するための吸入式医薬組成物及びその調製法 Download PDFInfo
- Publication number
- JP2015183004A JP2015183004A JP2015060820A JP2015060820A JP2015183004A JP 2015183004 A JP2015183004 A JP 2015183004A JP 2015060820 A JP2015060820 A JP 2015060820A JP 2015060820 A JP2015060820 A JP 2015060820A JP 2015183004 A JP2015183004 A JP 2015183004A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhalation
- type pharmaceutical
- gas
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 132
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 74
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title description 4
- 239000007789 gas Substances 0.000 claims abstract description 154
- 239000001257 hydrogen Substances 0.000 claims abstract description 104
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 104
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 98
- 239000003814 drug Substances 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 52
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000001301 oxygen Substances 0.000 claims abstract description 38
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 18
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004502 levodopa Drugs 0.000 claims abstract description 18
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 14
- 229960003337 entacapone Drugs 0.000 claims abstract description 14
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims abstract description 14
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims abstract description 13
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims abstract description 13
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims abstract description 13
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims abstract description 13
- 229960002028 atropine sulfate Drugs 0.000 claims abstract description 13
- 229960002802 bromocriptine Drugs 0.000 claims abstract description 13
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims abstract description 13
- 229960004205 carbidopa Drugs 0.000 claims abstract description 13
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract description 13
- 229960002646 scopolamine Drugs 0.000 claims abstract description 13
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims abstract description 13
- 229960003946 selegiline Drugs 0.000 claims abstract description 13
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims abstract description 13
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 6
- 239000011261 inert gas Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- -1 cinemet Chemical compound 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 8
- 238000005868 electrolysis reaction Methods 0.000 claims description 7
- 230000008016 vaporization Effects 0.000 claims description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 229940001089 sinemet Drugs 0.000 abstract 1
- 238000000889 atomisation Methods 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】第1ガスが水素を含み、吸入式医薬組成物中の水素のガス体積濃度は2〜96%であり、霧化薬がレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである吸入式医薬組成物。第2のガスとして空気、水蒸気、不活性ガス、酸素又はそれらの組み合せガスを含む吸入式医薬組成物。
【効果】吸入式医薬組成物は、水素の使用によって患者の体内の有害なラジカルを除去し、一方、霧化薬を使用することによって患者における薬の吸収効果を増加させ、使用者に対するより良好な治療効果を有する利便性を兼ね備えたパーキンソン病のための治療方法を提供できる。
【選択図】なし
Description
1.発明の分野
本発明は、吸入式医薬組成物及びその調製法に関し、より詳細には、パーキンソン病の治療に使用される吸入式医薬組成物及びその調製法に関する。
パーキンソン病の臨床症状を扱うとき、しばしば観察される三大特徴は振戦、動作緩慢及び硬直である。脳内でのドーパミンの減少がパーキンソン病を引き起こすと考えられている。したがって、パーキンソン病の治療は前駆体の形態でドーパミンを投与することによって行われ、それはドーパミン代謝を調節し、又はドーパミン作動薬を使用する。パーキンソン病のためのいくつかの既知の治療薬があり、典型的な例としては、レボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン及びセレギリンが挙げられる。しかしながら、これらの薬物には、長期投与後の薬物に対する耐性、副作用、疾患の進行防止の失敗など、いくつかの難点がある。
(S1)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S2)薬液を霧化して霧化薬を生成する工程であって、霧化薬はレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである、工程;及び
(S3)第1ガスと霧化薬とを混合して吸入式医薬組成物を生成する工程であって、吸入式医薬組成物中の水素のガス体積濃度は2〜96%の間である、工程。
(S21)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S22)薬液を霧化して霧化薬を生成する工程であって、霧化薬はレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである、工程;
(S23)第2ガスを調製する工程;及び
(S24)第1ガス、第2ガス及び霧化薬を混合して吸入式医薬組成物を生成する工程。
(S1)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S2)薬液を霧化して霧化薬を生成する工程であって、霧化薬はレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである、工程;及び
(S3)第1ガスと霧化薬とを混合して吸入式医薬組成物を生成する工程であって、吸入式医薬組成物中の水素のガス体積濃度は2〜96%の間である、工程。
(S21)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S22)薬液を霧化して霧化薬を生成する工程であって、霧化薬はレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである、工程;
(S23)第2ガスを調製する工程;及び
(S24)第1ガス、第2ガス及び霧化薬を混合して吸入式医薬組成物を生成する工程。
Claims (20)
- 第1ガス及び霧化薬を含むパーキンソン病を治療するための吸入式医薬組成物であって、前記第1ガスは水素を含み、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜96%の間であり、前記霧化薬はレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項1に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記第1ガスはさらに酸素を含む、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項2に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記第1ガスは水の電気分解から生成される水素と酸素のガス混合物であり、前記水素と前記酸素の体積比は2:1である、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項2に記載のパーキンソン病を治療するための吸入式医薬組成物であって、さらに前記吸入式医薬組成物中の前記水素のガス体積濃度を減少させるために第2ガスを含み、該第2ガスは空気、水蒸気、不活性ガス、酸素又はそれらの任意の組み合わせを含む群から選択されるガスである、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項1に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜66.66%の間である、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項1に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は4.7〜66.66%の間である、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項1に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は60〜66.66%の間である、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項1に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は66.66%よりも大きい、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項1に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記霧化薬は薬液を霧化又は気化させることによって生成される、パーキンソン病を治療するための吸入式医薬組成物。
- 請求項9に記載のパーキンソン病を治療するための吸入式医薬組成物であって、前記薬液はレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである、パーキンソン病を治療するための吸入式医薬組成物。
- パーキンソン病を治療するための吸入式医薬組成物の調製法であって、それは以下の工程:
(S1)第1ガスを調製する工程であって、前記第1ガスは水素を含む、工程;
(S2)薬液を霧化して霧化薬を生成する工程であって、前記霧化薬はレボドパ、シネメット、硫酸アトロピン、スコポラミン、ドーパミン作動薬、メシル酸ブロモクリプチン、セレギリン、カルビドパ、エンタカポン又はそれらの任意の組み合わせである、工程;及び
(S3)前記第1ガスと前記霧化薬とを混合して前記吸入式医薬組成物を生成する工程であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜96%の間である、工程、
を含む、パーキンソン病を治療するための吸入式医薬組成物の調製法。 - 請求項11に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、さらに前記工程(S2)の後に以下の工程:
(S23)第2ガスを調製する工程、
を含む、パーキンソン病を治療するための吸入式医薬組成物の調製法。 - 請求項12に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記工程(S3)では、前記吸入式医薬組成物は前記第1ガス、前記第2ガス及び前記霧化薬を混合することから生成される、パーキンソン病を治療するための吸入式医薬組成物の調製法。
- 請求項12に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記第2ガスは前記吸入式医薬組成物中の前記水素のガス体積濃度を減少させるために使用される、パーキンソン病を治療するための吸入式医薬組成物の調製法。
- 請求項12に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記第2ガスは空気、水蒸気、不活性ガス、酸素又はそれらの任意の組み合わせを含む群から選択されるガスである、パーキンソン病を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記工程(S1)では、前記第1ガスは水を電気分解することによって生成され、前記第1ガスは水素と酸素のガス混合物を含み、前記水素と前記酸素の体積比は2:1である、パーキンソン病を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜66.66%の間である、パーキンソン病を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は4.7〜66.66%の間である、パーキンソン病を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は60〜66.66%の間である、パーキンソン病を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載のパーキンソン病を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は66.66%よりも大きい、パーキンソン病を治療するための吸入式医薬組成物の調製法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW103110987A TWI589308B (zh) | 2014-03-25 | 2014-03-25 | 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法 |
TW103110987 | 2014-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015183004A true JP2015183004A (ja) | 2015-10-22 |
Family
ID=54155661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015060820A Pending JP2015183004A (ja) | 2014-03-25 | 2015-03-24 | パーキンソン病を治療するための吸入式医薬組成物及びその調製法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9381152B2 (ja) |
JP (1) | JP2015183004A (ja) |
KR (1) | KR20150111325A (ja) |
CN (1) | CN104940224A (ja) |
DE (1) | DE102015104358A1 (ja) |
TW (1) | TWI589308B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015205863A (ja) * | 2014-04-18 | 2015-11-19 | リン, シン−ユンLin, Hsin−Yung | 関節炎を治療するための吸入式医薬組成物及びその調製法 |
JP2020079227A (ja) * | 2018-06-29 | 2020-05-28 | MiZ株式会社 | パーキンソン病症状の改善又は予防のための組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106562945A (zh) * | 2015-10-11 | 2017-04-19 | 云南帕精生物科技有限公司 | 一类治疗帕金森病药物 |
CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529724A (ja) * | 2001-06-05 | 2004-09-30 | アレックザ モレキュラー デリヴァリー コーポレイション | 吸入療法に使用するためのエアロゾル形成装置 |
JP2006507218A (ja) * | 2002-03-20 | 2006-03-02 | アドバンスト インハレーション リサーチ,インコーポレイテッド | レボドパの肺送達 |
WO2007021034A1 (ja) * | 2005-08-19 | 2007-02-22 | Shigeo Ohta | 生体内の有害な活性酸素及び/又はフリーラジカル除去剤 |
JP2008518976A (ja) * | 2004-11-07 | 2008-06-05 | エフ. ギルフォード ティモシー | 還元型グルタチオン経口投与のためのリポソーム処方物 |
JP2013146373A (ja) * | 2012-01-19 | 2013-08-01 | Tatsunori Yamaji | 水素生成装置 |
WO2013183448A1 (ja) * | 2012-06-04 | 2013-12-12 | ミズ株式会社 | 生体用高濃度水素ガス供給装置 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283352A (en) | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
CN101287476A (zh) * | 2005-08-19 | 2008-10-15 | 太田成男 | 机体内的有害活性氧类和/或自由基清除剂 |
US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
TW201304822A (zh) | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
CN203291353U (zh) * | 2013-06-19 | 2013-11-20 | 林信涌 | 保健气体产生器 |
-
2014
- 2014-03-25 TW TW103110987A patent/TWI589308B/zh active
- 2014-07-16 CN CN201410338399.4A patent/CN104940224A/zh active Pending
-
2015
- 2015-03-20 US US14/664,465 patent/US9381152B2/en active Active
- 2015-03-24 JP JP2015060820A patent/JP2015183004A/ja active Pending
- 2015-03-24 DE DE102015104358.0A patent/DE102015104358A1/de not_active Withdrawn
- 2015-03-25 KR KR1020150041575A patent/KR20150111325A/ko not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529724A (ja) * | 2001-06-05 | 2004-09-30 | アレックザ モレキュラー デリヴァリー コーポレイション | 吸入療法に使用するためのエアロゾル形成装置 |
JP2006507218A (ja) * | 2002-03-20 | 2006-03-02 | アドバンスト インハレーション リサーチ,インコーポレイテッド | レボドパの肺送達 |
JP2008518976A (ja) * | 2004-11-07 | 2008-06-05 | エフ. ギルフォード ティモシー | 還元型グルタチオン経口投与のためのリポソーム処方物 |
WO2007021034A1 (ja) * | 2005-08-19 | 2007-02-22 | Shigeo Ohta | 生体内の有害な活性酸素及び/又はフリーラジカル除去剤 |
JP2013146373A (ja) * | 2012-01-19 | 2013-08-01 | Tatsunori Yamaji | 水素生成装置 |
WO2013183448A1 (ja) * | 2012-06-04 | 2013-12-12 | ミズ株式会社 | 生体用高濃度水素ガス供給装置 |
Non-Patent Citations (2)
Title |
---|
FU Y. ET AL.: "Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a r", NEUROSCIENCE LETTERS, vol. 453, JPN6016012549, 2009, pages 81 - 85, XP025968081, ISSN: 0003291176, DOI: 10.1016/j.neulet.2009.02.016 * |
OHTA SHIGEO: "Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therape", CURRENT PHARMACEUTICAL DESIGN, vol. 17, JPN6016012553, 2011, pages 2241 - 2252, XP055535704, ISSN: 0003291177, DOI: 10.2174/138161211797052664 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015205863A (ja) * | 2014-04-18 | 2015-11-19 | リン, シン−ユンLin, Hsin−Yung | 関節炎を治療するための吸入式医薬組成物及びその調製法 |
JP2020079227A (ja) * | 2018-06-29 | 2020-05-28 | MiZ株式会社 | パーキンソン病症状の改善又は予防のための組成物 |
JP7312341B2 (ja) | 2018-06-29 | 2023-07-21 | MiZ株式会社 | パーキンソン病症状の改善又は予防のための組成物 |
Also Published As
Publication number | Publication date |
---|---|
TW201536361A (zh) | 2015-10-01 |
CN104940224A (zh) | 2015-09-30 |
TWI589308B (zh) | 2017-07-01 |
DE102015104358A1 (de) | 2015-10-29 |
US20150272866A1 (en) | 2015-10-01 |
US9381152B2 (en) | 2016-07-05 |
KR20150111325A (ko) | 2015-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3193761U (ja) | ガス発生健康機器 | |
JP2015183005A (ja) | アルツハイマー病を治療するための吸入式医薬組成物及びその調製法 | |
US9763946B2 (en) | Inhalation-type pharmaceutical composition for the treatment of lung cancer and preparation method thereof | |
JP2015183004A (ja) | パーキンソン病を治療するための吸入式医薬組成物及びその調製法 | |
JP2015205864A (ja) | 痛風を治療するための吸入式医薬組成物及びその調製法 | |
JP2015183006A (ja) | 心疾患を治療するための吸入式医薬組成物及びその調製法 | |
JP2015205863A (ja) | 関節炎を治療するための吸入式医薬組成物及びその調製法 | |
TWI594772B (zh) | 一種用於治療高血壓之吸入式醫藥組成物及其備製方法 | |
TWI590838B (zh) | 一種用於治療糖尿病之吸入式醫藥組成物及其備製方法 | |
US20150297513A1 (en) | Inhalation-type pharmaceutical composition for the treatment of kidney disease and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150806 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160405 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161018 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170117 |